“…This has mainly concerned the B.1.617.2 (delta) variant that was first identified in India in December 2020 and became dominant in the European Region by June/July 2021 [ 8 ]. A number of post-authorization studies originating from different countries in mid-2021 have shown that despite SARS-CoV-2 evolution, vaccination continues to decrease the risk of contracting the virus [ 2 , 9 , 10 , 11 ], while in the case of breakthrough infection, the risk of severe disease, hospitalization, and death is significantly reduced [ 12 , 13 , 14 , 15 ]. However, SARS-CoV-2, similarly to other respiratory viruses, reveals a strong seasonal pattern in the temperate zone, with infection rates rising in the autumn-winter season [ 16 , 17 , 18 ].…”